Monthly Newsletter June 2023


EFMC-ASMC 2023 will focus on the most recent advances in new synthetic methodologies, total synthesis, chemical biology, process and medicinal chemistry, and automation & AI approaches in synthesis and drug discovery.

The symposium programme will feature an opening lecture by Prof. Jeffrey BODE (ETH ZURICH, CH), followed by 26 invited lectures equally selected from industry and academia. Additionally, 10 oral communications have been selected from submitted abstracts.

Have a look at the final programme!

If you still want to submit an abstract for poster presentation, do not miss the deadline until July 4!


For the fourth edition of the prize, the selection committee designated Zuzanna Kozicka (Friedrich Miescher Institute for Biomedical Research (University of Basel), Switzerland) as the winner of the 2023 EFMC-YSN PhD Prize. 

Margarida Espadinha (University of Antwerp, Belgium) has been recognised as the most meritorious runner-up.

Zuzanna Kozicka Zuzanna Kozicka graduated from the University of Edinburgh and conducted research projects e.g. at ETH Zürich (Prof. Ban) and the University of Dundee (Prof. Ciulli). In her graduate studies at FMI Basel, Zuzanna focused on molecular glue degraders, discovering degraders of cyclin K, and uncovering novel molecular glue modes of action.

The prize will consist of a diploma500€ and an invitation to deliver an oral communication at the EFMC Young Medicinal Chemists' Symposium (EFMC-YMCS). The 2023 winner will also receive a free registration and a 500€ travel grant to attend both the IX EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry (EFMC-ASMC 2023) and the 10th EFMC Young Medicinal Chemists' Symposium (EFMC-YMCS 2023) which will take place in Zagreb, Croatia on September 3-7 & September 7-8, 2023.


EFMC is funding grants for EFMC organised events with the aim to support the participation of young academic scientists. In 2023, the following grants have been distributed:

17th EFMC Short Course in Medicinal Chemistry

  • Giulia BONONI, University of Pisa, Italy

ACSMEDI-EFMC Medicinal Chemistry Frontiers 2023

  • Jonathan NUE, University of Geneva, Switzerland
  • Federico RIU, Uppsala University, Sweden
  • Katharina Erlitz, WWU Münster, Germany
  • Julia Schoenfeld, Goethe University, Germany

EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry (EFMC-ASMC 2023) & 10th EFMC Young Medicinal Chemists’ Symposium (EFMC-YMCS 2023)

  • Jihed AZZOUZ, University of Côte d'Azur, France
  • Carola CASTIELLO, Sapienza University of Rome, Italy
  • Isabella FERRARA, University of Zurich, Switzerland
  • Alex James HALLATT, Newcastle University, United Kingdom
  • Yudibeth SIXTO, University of Granada, Spain
  • Vanrajsinh THAKOR, FAU Erlangen-Nürnberg, Germany
  • Iva ZONJIC, IRB, Croatia

Two additional grants have been funded by Prof. Georg Winter, winner of the 2023 EFMC Prize for a Young Medicinal Chemist or Chemical Biologist in Academia, who donated his prize money to support the participation of young researchers.

  • Jelena KESIC, University of Novi Sad, Serbia
  • Katarzyna MALARZ, University of Silesia in Katowice, Poland

EFMC International Symposium on Chemical Biology (EFMC-ISCB 2023)

  • Beerkens BERT, Leiden University, The Netherlands
  • Sara HUMMEID, University of Lisbon, Portugal
  • Noemí MARTÍNEZ CONDE, University of Barcelona, Spain
  • Athanasios PANAGIOTOPOULOS, University of Crete, Greece
  • Janne TAMPIO, University of Eastern Finland, Finland


This contribution will focus on the recently published article on “Discovery of SI 1/20 and SI 1/22 as Mutual Prodrugs of 5-Fluorouracil and Imidazole-Based Heme Oxygenase 1 Inhibitor with Improved Cytotoxicity in DU145 Prostate Cancer Cells” by Loredana Salerno, Valeria Sorrenti, Valeria Pittalà, Valeria Consoli, Maria N. Modica, Giuseppe Romeo, Agostino Marrazzo, Michela Giuliano, Pawe''.chr('322').'' Zajdel, Luca Vanella, and Sebastiano Intagliata, published in ChemMedChem.

5-Fluorouracil (5-FU) is a common drug in oncology used as either monotherapy or combined therapy against several tumours including prostate, gastric, colorectal, pancreatic, and breast cancer. It belongs to the group of chemotherapy drugs known as antimetabolites; as a fluorinated derivative of the pyrimidine base uracil, it appears to act through inhibition of the enzyme thymidylate synthase, which disrupts DNA synthesis. Despite its clinical use, 5-FU has several limitations, for example: low chemical stability, short plasma half-life, poor bioavailability, drug resistance, and low tumour selectivity; the latter can lead to toxicity in healthy cells. Various pro-drugs and co-drugs have been described to overcome the lack of selectivity of 5-FU, and also to try to improve its biological activity and targeted delivery. In co-drugs, the carrier used is another biologically active drug. In this paper, L. Salerno et al prepared co-drugs of 5-FU and heme oxygenase-1 (HO-1) inhibitors.

HO-1 is a heat shock protein that has been found to be overexpressed in many cancer types, with inhibition shown to decrease viability of some cancer cells. The design of the co-drugs was based on imidazole-containing HO-1 inhibitors previously reported by the same group. A hydroxymethyl-derived 5-FU intermediate was connected via a succinyl cleavable linker to the hydroxy group of the HO-1 inhibitors, thus, the codrugs contained two hydrolysable esters functionalities. With the compounds synthesised, in vitro hydrolysis studies showed that one compound (SI 1/22) was readily hydrolysed in a porcine esterase solution with a half-life (t1/2) of 5.6 h, and in PBS with t1/2 = 6.3 h. Predicted physicochemical properties suggested that the co-drug had a more suitable drug-like profile than 5-FU alone. The same software also predicted no serious toxicity for SI 1/22, as compared to the high predicted toxicity of 5-FU. Predicted ADME properties with a PreADMET application indicated that they would have suitable bioavailability, but also that they were potential substrates of CYP3A4 and had strong binding to PPB, as opposed to 5-FU.

Regarding the biological activity of the codrugs, their effect on viability was assessed in two cancer cell lines that overexpress HO-1, namely A549 (lung) and DU145 (prostate). In DU145 cells, SI 1/22 had a stronger effect on viability than 5-FU alone in a dose-dependent manner. The cytotoxic effect of SI 1/22 on these cells was also higher than a 1:1 mixture of 5-FU and the corresponding HO-1 inhibitor. SI 1/22 was also shown to increase the levels of reactive oxygen species (ROS) in DU145 cells. The effect of SI 1/22 on healthy cells (BHP-1, a human benign prostatic hyperplasia cell line) was lower than 5-FU, thus indicating that they could be more selective for cancer vs non-cancer cells than the original drug. In terms of activity on target, the authors evaluated the effect of the compounds on HO enzymatic activity. In cell-free systems, the co-drugs were less active for HO-1 than their parent inhibitors; this was expected as these compounds release the active inhibitors after being hydrolysed in cells – the released hydroxy group is pivotal for enzyme inhibition. Conversely, in cell lysates from DU145 cells, SI 1/22 showed a significant reduction of HO enzymatic activity.

All in all, this paper discloses a new approach to improve the efficacy and decrease the toxicity of the common chemotherapy drug 5-FU, based on the use of codrugs from 5-FU and HO-1 inhibitors. Preliminary studies suggest an improvement in efficacy and a decrease in toxicity of the original drug, which support the promise of co-drugs in potentially overcoming some of the limitations of combinational therapy. Future studies could consider the use of nanoparticles to avoid an early release of the drug and to improve some of the predicted ADMET properties of the compounds.

Read the Paper!


The ChemBioChem – EFMC Special Issue on “Advances in Chemical Probing Concepts for Chemical Biology applications” aims at highlighting the role of chemical probes in biomedical discovery today and at identifying emerging trends and technologies in the discovery of the next wave of drug targets that will advance medical progress in the next decade.

Deadline for contributions end of December 2023, submit @

Guest Editors: Dr. Paola B. Arimondo,Dr. Sebastian Essig, Dr. Ulrich Schopfer, Dr. Arne Rufer

Chemical Probes

Chemical probes allow to identify, validate and confirm novel targets for therapeutic applications, enable the development of drug candidates, and open the way to new therapeutic strategies, vaccines and diagnostic tools.


In this edition, our MedChemBioConversations is with Dr Exequiel Porta from Durham University, United Kingdom.

Get to know him better by reading the interview below:

Exequiel Porta

How did you get interested in Medicinal Chemistry?

I became interested in medicinal chemistry during my undergraduate studies in Biotechnology (National University of Rosario, Argentina), where I was fascinated by the potential for chemistry to address important problems in healthcare. As I learned more about the role of chemistry in drug discovery and development, I became increasingly interested in the interdisciplinary nature of medicinal chemistry and the potential for collaboration between chemists, biologists, and clinicians to develop new therapies.

My passion for medicinal chemistry continued to grow during my graduate studies, where I had the opportunity to work on a project focused on the design and synthesis of novel small molecules for the treatment of neglected tropical diseases (NTDs), such as leishmaniasis, Chagas disease, HAT, malaria, etc., as well as for cancer. This experience solidified my interest in drug discovery and showed me the potential impact that medicinal chemistry research can have on patients' lives.

Since then, I have been fortunate to have the opportunity to work on a range of projects in medicinal chemistry and chemical biology, from designing inhibitors of infectious disease targets to developing novel chemical probes for target discovery in NTDs. The diversity of these projects has allowed me to develop a broad perspective on the field and has reinforced my passion for using chemistry to address important problems in healthcare.

What was the topic of your PhD project?

My interest in prenylated compounds, a privileged structure in nature, together with the enormous experience of my supervisor in the prenylated’s world, Prof Guillermo Labadie, led me to pursue a PhD focused on using these compounds as a basis for generating novel chemical and biological tools to expand our understanding of foundational biology, particularly regarding organisms that produce neglected tropical diseases (NTDs). Through my research, I aimed to develop new strategies for identifying and targeting NTD-producing organisms, which pose a significant public health threat in many parts of the world.

My PhD thesis was completed in 2015 at National University of Rosario, and was recognized and awarded by the Argentine Society of Organic Chemistry as the best Argentine thesis of the biennium (2015-2016). This recognition was a testament to the innovative approach and significant contributions of my research, which has the potential to drive new discoveries in the field of medicinal chemistry.

My first postdoctoral experience was in Argentina, working at the Rosario Chemistry Institute and the Institute of Molecular and Cellular Biology of Rosario. My second postdoctoral position was at the Department of Chemistry of Durham University, in the United Kingdom.

Where are you currently working and are your current research interests?

Currently, I am working at Durham University (United Kingdom) as a Research Fellow (Marie Skodowska–Curie actions, Durham University, and the Network for Neglected Tropical Diseases).

My current research interests focus on the use of activity-based protein profiling (ABPP) to develop new strategies for identifying and targeting enzymes involved in the pathogenesis of neglected tropical diseases (NTDs). ABPP is a powerful chemoproteomic tool that allows us to selectively visualize and measure the activity of enzymes within complex biological systems, providing valuable insights into the mechanisms underlying disease.

My research in this area aims to expand our understanding of the molecular mechanisms driving NTD pathogenesis, with the ultimate goal of identifying new therapeutic targets and developing more effective treatments for these devastating diseases. I am particularly interested in exploring the use of ABPP in combination with other technologies, such as high-throughput screening and medicinal chemistry, to accelerate the discovery and development of new drugs for NTDs.

How would you explain what your research area is to non-scientists?

My research area focuses on studying diseases that are often overlooked and underfunded, called neglected tropical diseases (NTDs). These diseases affect more than 1 billion of people in low-income countries and can cause a lot of suffering and disability.

To help find better treatments for NTDs, I use a special technique called activity-based protein profiling (ABPP), which allows me to study the specific proteins in the pathogens that are involved in causing these diseases. By understanding how these proteins work and interact with each other (this is called the interactome), we can identify new ways to stop the disease from progressing and develop more effective drugs.

To help explain my research approach, I often use the analogy of archery. Just as an archer uses a bow and arrow to hit a target, I use specialized techniques and chemical probes to study proteins in the body that are involved in disease. In this analogy, the bow represents the various techniques I use, such as activity-based protein profiling (ABPP), while the arrow represents the chemical probes that I use to target specific proteins of interest. The target itself represents the sum of all the proteins in an organism, and the centre of the target is the specific proteins that I want to study. Just as an archer aims for the centre of the target, I aim to use my techniques and chemical probes to study the proteins that are most relevant to disease. By hitting these targets, I can gain a better understanding of the mechanisms behind disease and identify new ways to develop more effective treatments.

What do you like best about your work?

As many scientists in the field of medicinal chemistry, I enjoy the opportunity to make a meaningful impact on human health by developing new treatments for diseases that can have a major impact on people's lives. This sense of purpose and contribution to society can be incredibly rewarding.

Additionally, I enjoy the intellectual challenge and creativity that comes with designing new chemical compounds and developing innovative approaches to studying disease. There is always more to learn and discover in this field, which can make for a stimulating and engaging work environment. Also, I am grateful for the collaborative nature of the work, which often involves working with other scientists and researchers across different disciplines to tackle complex problems. The opportunity to work with others who are passionate about advancing scientific knowledge can be a fulfilling and motivating experience.

Of course, collaborating with other scientists and networking is also critical to successful research in this field. Finally, writing reports and publications and supervising PhD and Master students are important aspects of communicating research findings and mentoring the next generation of scientists.

What do you consider your greatest achievement in your scientific career?

It can be difficult to pinpoint a single greatest achievement in my scientific career. While I have received individual awards that I am proud of, I would say that one of the most fulfilling experiences was the day my first master's student, Dr. Jaime Isern, obtained his degree. Being able to train and mentor the next generation of scientists is incredibly inspiring and rewarding. It's exciting to see my students grow and develop their own research interests, and I feel a sense of pride and satisfaction in their accomplishments. Ultimately, they will carry on the work and push the boundaries of scientific discovery even further, and I am honoured to have played a part in their journey.

Which of your papers are you most proud of and why?

One of the papers that I am most proud of is "Discovery of Leishmania Druggable Serine Proteases by Activity-Based Protein Profiling," which was published in Frontiers in Pharmacology in 2022. This paper is particularly meaningful to me because it represents the first of a series of publications that will highlight the use of chemoproteomic tools in NTD-producing parasites, a project that I am currently leading at Durham University. Through this research, we are exploring new ways to identify and target the proteins that are responsible for causing diseases like leishmaniasis, and I am excited about the potential impact that our work could have on global health.

Porta, E.O.J., Isern, J.A., Kalesh, K., Steel, P.G. 2022. Discovery of Leishmania Druggable Serine Proteases by Activity-Based Protein Profiling. Front Pharmacol. 13, 929493. doi: 10.3389/fphar.2022.929493.

What are the features of a successful PhD student or postdoc?

PhD students and postdocs need to be self-motivated and have a strong work ethic to be successful. They need to be able to work independently and manage their time effectively. Another key feature is critical thinking and problem-solving skills, adaptability, and resilience. Also, a clear communication of ideas, results, and challenges is essential to succeed as a PhD student or postdoc. PhD students and postdocs often work as part of a larger research group, so the ability to work effectively in a team is critical for the sharing of ideas, knowledge, and resources to accomplish research goals. Finally, a love for science and a genuine curiosity about the world are key ingredients for success in a PhD program or postdoc position.

What advice would you give to someone who wants to know more about your field?

If someone wants to know more about my field, I would suggest several things: Start by reading review articles and textbooks on medicinal chemistry to gain a solid foundation of the field's principles and techniques. Attend conferences, workshops, and seminars to learn about the latest research and network with other scientists. Consider pursuing an internship or research experience in a medicinal chemistry lab to gain hands-on experience with the techniques and methods used in the field. Join professional organizations and subscribe to relevant journals to stay up-to-date on the latest research and news in the field. Finally, be curious and ask questions! The field of medicinal chemistry is constantly evolving, and there is always something new to learn.

Have you experienced any unfair situations during your scientific career? How would you advise scientists facing similar situations?

Unfortunately, unfair situations can occur in any career, including scientific research. However, if a scientist is facing an unfair situation, my advice would be to first seek support from colleagues or mentors or institutional resource, and document the situation as much as possible. It may also be helpful to reach out to relevant professional organizations or advocacy groups for guidance and resources. It is important to remember that addressing unfair situations can take time and persistence, but seeking help and speaking out can ultimately lead to positive change. I have personally witnessed and experienced unfair situations in my scientific career, and I believe it is important to seek guidance and support in such situations.

What is the most embarrassing thing you have done in the lab while doing experiments, e.g. explosions?

When I first started working in a laboratory, in my very first day, I accidentally broke a mortar. But it taught me a valuable lesson - that mistakes and accidents are an inherent part of the scientific process and that it's often through failure that we learn the most. As a result, I've always believed that if you're not breaking something in the lab, you're probably not pushing the boundaries of what's possible.

What are your recommendations for a book, podcast, website, blog, YouTube channel or film?

Films: Radioactive; Breaking bad (series); Perfume, the Story of a Murderer.

Books: The Disappearing Spoon: And Other True Tales of Madness, Love, and the History of the World from the Periodic Table of the Elements by Sam Kean; H2O: A Biography of Water by Phillip Ball; Vector by Robin Cook.

Which scientist do you admire the most and why?

There are many scientists who have made significant contributions to the field of medicinal chemistry, and it is difficult to choose just one. However, if I had to pick, I would say Carolyn Bertozzi, because she is a renowned chemist and biochemist who has made significant contributions to the fields of chemical biology and glycobiology. I admire her not only for her ground-breaking research but also for her commitment to promoting diversity and inclusion in science. As a leader in her field, she has inspired many young scientists to pursue careers in STEM and has worked to create opportunities for underrepresented groups in academia. Her dedication to interdisciplinary research and her ability to combine chemistry, biology, and medicine in innovative ways is truly remarkable, and I am inspired by her work and her vision for the future of science.

Which field of medicinal chemistry do you consider the most promising for the future?

Currently, there are several exciting areas in medicinal chemistry that show great potential for future developments. Some of the most promising fields of medicinal chemistry for the future include the development of targeted therapies for cancer and other diseases, the discovery of novel antibiotics and antiviral drugs to combat emerging infectious diseases, the design of new drugs for neurological disorders, proteolysis targeting chimera (PROTAC), nanotechnology-based drug delivery systems, and the development of personalized medicine approaches based on genomics and proteomics. They are all promising areas that could have a significant impact on human health in the future. Additionally, the use of artificial intelligence and machine learning in medicinal chemistry is also a rapidly growing area that holds great promise for accelerating drug discovery and development.

What would you expect to be the next major breakthrough in medicinal chemistry?

I would say that personalized medicine is one the most promising area in medicinal chemistry and, possibly, the next major breakthrough. Recent advances in genomics, proteomics, and related fields are making it possible to tailor treatments to an individual's specific genetic and disease profile. This will be further accelerated by the integration of artificial intelligence into medical development programs, which can help identify personalized treatment options based on large-scale data analysis.


The Young MedChem Forum of the SCT (French medicinal chemistry society) was created in early 2022 to promote medicinal chemistry and chemical biology in the community of chemistry students and young scientists.

Several initiatives are ongoing among which “AskMeAnything” sessions. Our first international session with Dr Jean Quancard (executive director discovery chemistry at Novartis, Basel) as special guest will stand virtually on June 20th at 6-7 pm CEST. A presentation about “Finding a job as a medicinal chemist: expectations from Industry” followed by Q/A are programmed. All future/current PhD students and post-docs are welcome. Spoken language: English

The registration is free but completion of this Google Form is mandatory.

SCT News


The Group for the Promotion of Pharmaceutical chemistry in Academia (GP2A) will host their 31st annual conference in Marseille - France, from 23rd to 25th August 2023. This annual event brings together participants from across Europe, with the aim of bringing together university and industrial researchers working in the field of medicinal chemistry and chemical biology.

This congress is known for its high scientific standing, its friendly atmosphere, and the intensity of the exchanges of experience that it allows between senior and young researchers (doctoral or post-doctoral students). Additionally, the winner of the best oral communication will be invited to deliver a lecture at the 2024 EFMC Young Medicinal Chemists’ Symposium (EFMC-YMCS), scheduled to take place in Rome, Italy on September 5-6, 2024.

Several internationally renowned speakers will share their research in plenary lectures:

  • Dr. Karine Alvarez (Université Aix-Marseille)
  • Prof. Jose I. Borrell (Universitat Ramon Llull, Barcelona)
  • Prof. Philipp Klahn (University of Gothenburg)
  • Prof. Philippe Loiseau (Université Paris Saclay)
  • Prof. Jose Marco-Contelles (IQOG-CSIC, Madrid)
  • Prof. Maria M. M. Santos (University of Lisboa)
  • Prof. Gianluca Sbardella (University of Salerno)
  • Prof. Anne Sophie Voisin-Chiret (Université de Caen Normandie) 

Over a hundred researchers from France, Ireland, Germany, United Kingdom, Spain, Portugal and further afield will participate in this congress. Information about GP2A 2023 will be updated on the GP2A website throughout the coming weeks ( and the details of past conferences are also available at this site.

After the success of GP2A 2022 in TCD Dublin-Ireland, we are so excited to get together in August 2023!



The MedChem Division of the German Chemical Society (GDCh) would like to invite you to the next #MedChemCASES online seminar which will be held on June 27 by Dr. Soufyan Jerhaoui.

The topic of the webinar will be Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies”

Avoidance of apoptosis is critical for the development and sustained growth of tumors. The pro-survival protein myeloid cell leukemia 1 (Mcl-1) is an anti-apoptotic member of the Bcl-2 family of proteins which is overexpressed in many cancers. Upregulation of Mcl-1 in human cancers is associated with high tumor grade, poor survival, and resistance to chemotherapy. Therefore, pharmacological inhibition of Mcl-1 is regarded as an attractive approach to treating relapsed or refractory malignancies. Herein, we disclose the design, synthesis, optimization, and early preclinical evaluation of a potent and selective small-molecule inhibitor of Mcl-1. Our exploratory design tactics focused on structural modifications which improve the potency and physicochemical properties of the inhibitor while minimizing the risk of functional cardiotoxicity. Despite being in the “non-Lipinski” beyond-Rule-of-Five property space, the developed compound benefits from exquisite oral bioavailability in vivo and induces potent pharmacodynamic inhibition of Mcl-1 in a mouse xenograft model.

Register for free here.

#GDCh (MedChem Division), #NextGenMedChem.



The BMCS is pleased to open nomination calls for the Capps Green Zomaya Memorial Awards 2024 and the BMCS Hall of Fame and Medal 2023, as well as some upcoming events.

  • 10th SCI/RSC Kinase Symposium on Inhibitor Design
  • 3rd Synthesis in Drug Discovery and Development
  • 3rd RSC Anglo-Nordic Medicinal Chemistry Symposium

Capps Green Zomaya Memorial Award 2024

The Biological and Medicinal Chemistry Sector of the Royal Society of Chemistry is pleased to invite nominations for the eleventh Capps Green Zomaya Memorial Award in medicinal or computational chemistry. The Award will be given to the individual judged to have made an important contribution to the discovery or development of new medicines. Nominations are invited for candidates, up to the age of 40, working in UK or international laboratories (candidates over the age of 40, who have taken career breaks, will be considered). A Royal Society of Chemistry commemorative medal and certificate will be awarded to accompany the prize of £2,000

Nominations should be submitted no later than 31 October 2023 to: RSC-BMCS Secretariat, Hg3 Conferences Ltd, email: 

For further details, please access the activities link on


BMCS Hall of Fame and Medal 2023 – Call for nominations.

The BMCS is pleased to announce the 2023 call for nominations for its Hall of Fame and associated medal which recognises chemists for outstanding, sustained, significant contributions to any area of interest to the BMCS, including medicinal chemistry, agriscience, bio-organic chemistry, and chemical biology. Independent nominations may be submitted by e-mail outlining the justification and including the nominee’s CV and publication list. Additional independent letters of support to reinforce the nomination are strongly encouraged. Nominees should be resident in the UK or continental Europe, or have spent a considerable proportion of their career there. There is no requirement to be an RSC or BMCS member. There are no age restrictions, and nominees may have an academic or industrial background. Nominations should be submitted by the end of September 2023 and the outcome will be communicated to nominators and nominees by mid-December 2023. Inductees will receive a medal and certificate, and will be invited to give a plenary lecture at an appropriate BMCS organized conference.

Independent nominations should be sent to the RSC-BMCS Secretariat, Hg3 Conferences Ltd, email: from 1 March to 30 September 2023.

For the full list of requirements and terms and conditions, please see the guidance notes above.




Activate Scientific is a European catalogue supplier with over 20 years of experience supplying high-quality multifunctional building blocks and complex scaffolds specialised for medicinal chemistry drug discovery. Our catalogue contains over 140,000 building blocks with express delivery from our German and UK offices. We also offer reliable scale-up and custom synthesis.

Read more


September 3-7, 2023
Zagreb, Croatia
IX International Symposium on Advances in Synthetic and Medicinal Chemistry (EFMC-ASMC)

September 7-8, 2023
Zagreb, Croatia
10th EFMC Young Medicinal Chemists' Symposium (EFMC-YMCS)

November 16-18, 2023
Basel, Switzerland
EFMC International Symposium on Chemical Biology (EFMC-ISCB)


June 22, 2023
Santiago de Compostela, Spain
IX Symposium of Medicinal Chemistry Young Researchers

July 5-7, 2023
Lille, France
RICT 2023

September 17-20, 2023
Chieti, Italy
National Meeting on Medicinal Chemistry (NMMC28)

September 20-22, 2023
Vila Real, Portugal
I International Meeting Molecules4Life

December 7, 2023
Oxford, United Kingdom
RSC-BMCS Postgraduate Symposium XVII


June 19-21, 2023
Santiago de Compostela, Spain
VIII SEQT Summer School

July 2-6, 2023
Urbino, Italy
European School of Medicinal Chemistry (ESMEC)

September 10-15, 2023
Vienna, Austria
Vienna Summer School Drug Design


Applications Scientist, Schrödinger, FRANCE
Read more

PI, Pompeu Fabra University, SPAIN
Read more

Post-doctoral assistant in Medicinal Chemistry, Geneva, SWITZERLAND
Read more

Post-doctoral assistant in Molecular Biology, Geneva, SWITZERLAND
Read more

Find us on social media

EFMC Facebook EFMC Twitter EFMC LinkedIn EFMC Instagram